Navigation Links
Aspreva and Roche Announce Preliminary Results for Phase III Study,Evaluating CellCept in Lupus Nephritis

lCept in the treatment of autoimmune indications and any future products for our targeting indications may be greater than anticipated; the risk that we may not sustain our profitability; our ability to attract and retain collaborations relating to the development and commercialization of new indications; competition from other pharmaceutical or biotechnology companies; our ability to raise additional financing required to fund further research and development, clinical studies, and obtain regulatory approvals, on commercially acceptable terms or at all; economic and capital market conditions; our ability to obtain and protect patents and other intellectual property rights; our ability to operate without infringing the intellectual property rights of others; our ability to comply with applicable governmental regulations and standards; currency exchange rates; and our ability to successfully attract and retain skilled and experienced personnel.

For a more thorough discussion of the risks associated with Aspreva's business, see the "Risk Factors" section in Aspreva's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed with the U.S. Securities and Exchange Commission at http://www.sec.gov and with securities regulatory authorities in Canada at http://www.sedar.com. Although we have attempted to identify important risks, uncertainties and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements, there may be other factors that cause actual results or events to differ from those expressed or implied in the forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Aspreva undertakes no obligation to revise or update any forward-looking statements as a result of n
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:10/17/2014)... 2014 According to ... Technique (Optical Coherence Tomography, Hyperspectral Imaging, Photoacoustic ... Neurology, Oncology, Cardiology) - Global Forecasts to ... Optical Imaging market over the forecast period ... $917.1 million in 2014 and is expected ...
(Date:10/17/2014)... 2014 The following is being released ... The Green Park Collaborative (GPC) will bring ... payers, medical device and pharmaceutical companies, as well ... 12, 2015 at its first ever workshop on ... treatments.  Participants will discuss study designs to evaluate ...
(Date:10/17/2014)... BALTIMORE , Oct. 17, 2014  Ameritox SM ... announced the appointment of Thomas Smith , M.D., ... lead a field-based team offering scientific resources for healthcare ... Smith has held leadership positions at a variety of ... will benefit both the pain and behavioral health sides ...
Breaking Medicine Technology:Optical Imaging Market Worth $1,669.2 Million by 2019 2Optical Imaging Market Worth $1,669.2 Million by 2019 3Optical Imaging Market Worth $1,669.2 Million by 2019 4Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Ameritox Appoints New Chief Medical Officer 2
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 2BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 3BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 4BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 5BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 6BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 7BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 8BNA Books' Announces Publication of New 2009 Cumulative Supplement to 'Pharmaceutical Law: Regulation of Research, Development, and Marketing' 9China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference 2China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference 3China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference 4China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference 5China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference 6China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference 7China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference 8
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive ... a platform to think outside the bra. She doesn’t try ... to raise awareness about women’s other lady parts. , "We ... say the color pink and everybody knows what you’re talking ... that it has not been won when it comes to ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... October 20, 2014 Rockynol Retirement ... Center on Oct. 14. The $11 million project will ... and a cooked-to-order kitchen with full-service restaurant style dining. ... choice for first class Assisted Living apartments,” said Kara ... deserve the highest quality of care and this investment ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... It’s hard to imagine what it’s like ... children around the world, it’s a reality. And while new ... are forced to walk barefoot on rocky terrain or sewage-lined ... with their friends. , Buckner International's Shoes for ... in October to encourage support for Air1 and while ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... developers of the AcceleDent System , ... that its application to market and distribute the product ... Goods Administration (TGA) . AcceleDent is classified ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091111/DA09142 ) , (Logo: ...
... Leeds have developed a simple technology which can be ... time" drug crystal formation. Ensuring drug crystals are ... efficiency of pharmaceutical manufacturers, operations. Using self-assembled monolayers, the ... into their desired product form with the correct shape ...
... Professionals ... Advice on Hearing Aids website. , ... (PRWEB) November 11, 2009 -- AdviceOnHearingAids.com, a national online resource for ... and professionals in the hearing aid business. Already considered an important resource for ...
... study suggests more potential hazards from the plastics chemical ... high levels of the controversial plastics chemical bisphenol A ... impotence and low sex drive, among Chinese factory workers, ... stressed that the workers were exposed to BPA levels ...
... COLORADO SPRINGS, Colo., Nov. 11 According to a ... percent) of U.S. Army Special Forces Operators exposed to ... Army, even if they were experiencing Posttraumatic Stress Disorder ... ) , The 18-month study, which included 68 U.S. ...
... ... A Terrible Mistake: The Murder of Frank Olson and the CIA’s Secret Cold War Experiments, ... other drugs in a series of biochemical experiments. , ... (Vocus) November 11, 2009 -- Most Americans remember vague details of ...
Cached Medicine News:Health News:AcceleDent System From OrthoAccel Technologies, Inc. Secures Medical Device Regulatory Clearance to Market in Australia 2Health News:AcceleDent System From OrthoAccel Technologies, Inc. Secures Medical Device Regulatory Clearance to Market in Australia 3Health News:Right first time: Pioneering new methods of drug manufacture 2Health News:Online Hearing Aid Information Website Redefines Hearing Aid Marketing 2Health News:BPA Tied to Impotence in Men 2Health News:BPA Tied to Impotence in Men 3Health News:U.S. Army Special Forces Operators Reluctant to Seek Treatment for Posttraumatic Stress Disorder 2Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 2Health News:Explosive New Book Exposes the CIA, LSD Experiments and Murder 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: